NO20064981L - Oksadiazolonderivater som PPAR delta agonister - Google Patents

Oksadiazolonderivater som PPAR delta agonister

Info

Publication number
NO20064981L
NO20064981L NO20064981A NO20064981A NO20064981L NO 20064981 L NO20064981 L NO 20064981L NO 20064981 A NO20064981 A NO 20064981A NO 20064981 A NO20064981 A NO 20064981A NO 20064981 L NO20064981 L NO 20064981L
Authority
NO
Norway
Prior art keywords
disorders
ppar
agonists
participate
compounds
Prior art date
Application number
NO20064981A
Other languages
English (en)
Inventor
Corinne Terrier
Baptiste Ronan
Stefanie Keil
Jean Merrill
Karen Chandross
Jochen Goerlitzer
Wolfgang Wendler
Daniel G Mcgarry
Maike Glien
Patrick Bernardelli
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20064981L publication Critical patent/NO20064981L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives oksadiazoloner og deres fysiologisk akseptable salter og fysiologisk funksjonelle derivater som viser PPAR 5 aktivitet. Det beskrives forbindelser med formel (I) der restene er som definert og deres fysiologisk akseptable salter samt fremgangsmåter for deres fremstilling. Forbindelsene er egnet for terapi og/eller prevensjon av forstyrrelser av fettsyremetabolisme og glukoseutnyttelsesforstyrrelser så vel som forstyrrelser der insulinresistens er involvert, neurodegenerative sykdommer og/eller demyelinerende forstyrrelser av sentral- og perifernervesystemet og/eller neurologiske forstyrrelser som involverer neuroinflammatoriske prosesser og/eller annen perifer neuropati.
NO20064981A 2004-04-01 2006-10-31 Oksadiazolonderivater som PPAR delta agonister NO20064981L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007879A EP1586573B1 (en) 2004-04-01 2004-04-01 Oxadiazolones, processes for their preparation and their use as pharmaceuticals
PCT/EP2005/002950 WO2005097786A1 (en) 2004-04-01 2005-03-19 Oxadiazolone derivatives as ppar delta agonists

Publications (1)

Publication Number Publication Date
NO20064981L true NO20064981L (no) 2006-12-28

Family

ID=34924545

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064981A NO20064981L (no) 2004-04-01 2006-10-31 Oksadiazolonderivater som PPAR delta agonister

Country Status (38)

Country Link
US (3) US20070179191A1 (no)
EP (3) EP1586573B1 (no)
JP (1) JP2007530612A (no)
KR (1) KR20060135857A (no)
CN (1) CN100582104C (no)
AR (1) AR050576A1 (no)
AT (1) ATE435225T1 (no)
AU (1) AU2005231916A1 (no)
BR (1) BRPI0509517A (no)
CA (1) CA2561627A1 (no)
CR (1) CR8572A (no)
CY (1) CY1109370T1 (no)
DE (2) DE602004004631D1 (no)
DK (1) DK1740583T3 (no)
DO (1) DOP2005000051A (no)
EC (1) ECSP066892A (no)
ES (1) ES2329484T3 (no)
GT (1) GT200500028A (no)
HK (1) HK1100408A1 (no)
HR (1) HRP20090493T1 (no)
IL (1) IL178056A0 (no)
MA (1) MA28495B1 (no)
MY (1) MY142431A (no)
NO (1) NO20064981L (no)
PA (1) PA8628701A1 (no)
PE (1) PE20060323A1 (no)
PL (1) PL1740583T3 (no)
PT (1) PT1740583E (no)
RS (1) RS51186B (no)
RU (1) RU2374243C2 (no)
SI (1) SI1740583T1 (no)
SV (1) SV2006002071A (no)
TN (1) TNSN06317A1 (no)
TW (1) TW200602342A (no)
UA (1) UA84203C2 (no)
UY (1) UY28837A1 (no)
WO (1) WO2005097786A1 (no)
ZA (1) ZA200606870B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
KR20080048504A (ko) 2005-09-29 2008-06-02 사노피-아벤티스 페닐- 및 피리디닐-1,2,4-옥사디아졸론 유도체, 이의제조방법 및 약제로서의 이의 용도
BRPI0616477A2 (pt) 2005-09-29 2011-06-21 Sanofi Aventis derivados de 2-amintiazóis e 2-amino-oxazóis, processos para a sua preparação e seus usos
EP1934206B1 (en) * 2005-09-29 2011-12-14 Sanofi Phenyl- and pyridyl-i, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
ES2399147T3 (es) 2006-09-08 2013-03-26 Rhode Island Hospital Tratamiento, prevención y reversión de una enfermedad hepática alcohólica
WO2008030604A2 (en) 2006-09-08 2008-03-13 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
EP2288605B1 (en) * 2008-06-09 2014-06-25 Sanofi Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
EP2288607B1 (en) 2008-06-09 2014-09-24 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
RU2010154279A (ru) 2008-06-09 2012-07-20 Санофи-Авентис (Fr) Аннелированные n-гетероциклические сульфонамиды с оксадиазолоновой концевой группой, способы их получения и их применение в качестве фармацевтических препаратов
CN102202672A (zh) 2008-10-10 2011-09-28 达拉生物科学公司 使用穗霉素衍生物治疗或预防疼痛的方法
LT3135672T (lt) * 2008-10-10 2020-05-25 Vm Discovery, Inc. Kompozicijos ir būdai skirti gydyti alkoholio vartojimo sutrikimus, skausmą ir kitas ligas
ES2439801T3 (es) * 2009-08-05 2014-01-24 Daiichi Sankyo Company, Limited Derivado de sulfona
EP2463279B1 (en) * 2009-08-05 2014-02-12 Daiichi Sankyo Company, Limited 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
WO2015061481A1 (en) 2013-10-23 2015-04-30 Dara Biosciences, Inc. Methods of treating liquid tumors using compositions comprising spicamycin derivatives

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256680A (en) 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
IL127296A (en) 1996-12-31 2003-01-12 Reddy Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
AU782404B2 (en) 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
BR0010605A (pt) 1999-04-28 2002-02-13 Aventis Pharma Gmbh Derivados ácidos de di-aril como ligantes de receptores ppar
EP1175421A1 (en) 1999-04-30 2002-01-30 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
AU773505B2 (en) 1999-06-18 2004-05-27 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
US6967201B1 (en) 1999-07-29 2005-11-22 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
ATE302754T1 (de) 1999-09-01 2005-09-15 Aventis Pharma Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
AU773777B2 (en) 1999-12-03 2004-06-03 Astrazeneca Ab Crystalline form of (S)-2 ethoxy-3-(4-(2-(4-methanesulfonyloxyphenyl) ethoxy) phenyl) propanoic acid
PT2055302E (pt) 2000-03-31 2014-12-03 Royalty Pharma Collection Trust Processo para a melhoria da sinalização de ilhéus em diabetes mellitus e para a sua prevenção
KR20030007548A (ko) 2000-04-25 2003-01-23 교린 세이야꾸 가부시키 가이샤 티아졸리딘디온 유도체의 신규한 안정한 결정 및 이의제조방법
AU5257401A (en) 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
CN1244561C (zh) 2000-05-11 2006-03-08 布里斯托尔-迈尔斯斯奎布公司 可用作生长激素促分泌素的四氢异喹啉类似物
JP2003534377A (ja) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
SK17252002A3 (sk) 2000-06-09 2003-05-02 Aventis Pharma Deutschland Gmbh Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JP4605990B2 (ja) 2000-12-21 2011-01-05 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な1,2−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用
EP1368011A1 (en) 2001-02-22 2003-12-10 SmithKline Beecham Corporation Method for treating ppar gamma mediated diseases
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
JP4436129B2 (ja) 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びppar−活性剤としてのその使用
US7205321B2 (en) * 2001-11-15 2007-04-17 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
US7595403B2 (en) 2003-04-01 2009-09-29 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
US7217727B2 (en) 2003-04-01 2007-05-15 Eli Lilly And Company Phospholipase inhibitors
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
EP1934206B1 (en) * 2005-09-29 2011-12-14 Sanofi Phenyl- and pyridyl-i, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
US20080255212A1 (en) 2008-10-16
MY142431A (en) 2010-11-30
CY1109370T1 (el) 2014-07-02
US20070179191A1 (en) 2007-08-02
TW200602342A (en) 2006-01-16
PL1740583T3 (pl) 2009-12-31
DOP2005000051A (es) 2005-12-15
BRPI0509517A (pt) 2007-09-11
PA8628701A1 (es) 2006-11-25
ECSP066892A (es) 2006-11-24
AU2005231916A1 (en) 2005-10-20
CN100582104C (zh) 2010-01-20
EP1740583A1 (en) 2007-01-10
ZA200606870B (en) 2008-04-30
HRP20090493T1 (en) 2009-10-31
WO2005097786A1 (en) 2005-10-20
RU2006138498A (ru) 2008-05-10
DK1740583T3 (da) 2009-10-19
US20080262052A1 (en) 2008-10-23
ES2329484T3 (es) 2009-11-26
AR050576A1 (es) 2006-11-08
SV2006002071A (es) 2006-01-30
CR8572A (es) 2007-12-04
EP1740583B1 (en) 2009-07-01
RS51186B (sr) 2010-10-31
US7709509B2 (en) 2010-05-04
MA28495B1 (fr) 2007-03-01
PT1740583E (pt) 2009-09-16
EP1586573A1 (en) 2005-10-19
PE20060323A1 (es) 2006-03-31
HK1100408A1 (en) 2007-09-21
EP2083006A1 (en) 2009-07-29
DE602005015204D1 (de) 2009-08-13
JP2007530612A (ja) 2007-11-01
GT200500028A (es) 2006-06-09
RU2374243C2 (ru) 2009-11-27
UA84203C2 (en) 2008-09-25
CA2561627A1 (en) 2005-10-20
KR20060135857A (ko) 2006-12-29
IL178056A0 (en) 2006-12-31
TNSN06317A1 (en) 2007-12-03
CN1938300A (zh) 2007-03-28
EP1586573B1 (en) 2007-02-07
SI1740583T1 (sl) 2009-12-31
DE602004004631D1 (de) 2007-03-22
ATE435225T1 (de) 2009-07-15
UY28837A1 (es) 2005-10-31

Similar Documents

Publication Publication Date Title
NO20064981L (no) Oksadiazolonderivater som PPAR delta agonister
NO20092293L (no) Sulfonyl-fenyl-2H-[1,2,4]oksodiazol-5-onderivater, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytiske midler
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
NO20081367L (no) Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
NO20081682L (no) 4-oksy-N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
NO20081369L (no) Fenyl- og pyridinyl-1,2,4-oksadiazolonderivater, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
Manyam et al. Effect of antiparkinson drug HP‐200 (Mucuna pruriens) on the central monoaminergic neurotransmitters
EP2083811B1 (en) Methods of treating down's syndrome, fragile x syndrome and autism
HK1104530A1 (en) Medicaments with hm74a receptor activity
NO20054408L (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
KR20170012449A (ko) 결정질 베타-d-니코틴아미드 리보시드의 제조 및 용도
US11278531B2 (en) Combination of ibudilast and riluzole and methods of using same
JP6977029B2 (ja) レット症候群を治療するためのプリドピジンの使用
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
US20170304351A1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
EP3820476A1 (en) Use of sgc stimulators for the treatment of mitochonrial disorders
NO20081681L (no) N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
WO2022225902A1 (en) Treatment of cns diseases with sgc stimulators
NO20081368L (no) Derivater av 2-amintiazoler og 2-aminooksazoler, fremgangsmate for fremstilling derav samt deres anvendelse som farmasoytika
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
WO2007039174A3 (en) Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation and their use as pharmaceuticals
NO20054397L (no) Cykloalkylderivater med bioisosteriske karboksylsyregrupper, fremgangsmate for fremstilling av disse og deres anvendelse som legemiddel
NO20055889L (no) 2-etoksy-3-fenylpropansyrederivater for behandling av fettforstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application